| Literature DB >> 27375769 |
Hui-Fang Chiu1, Ying-Hua Wu2, You-Cheng Shen3, Shing-Jung Wang4, Kamesh Venkatakrishnan2, Chin-Kun Wang2.
Abstract
BACKGROUND: Si-Wu-Tang (SWT) is used to treat various gynecological disorders in Chinese medicine. This study investigated the antioxidant and physiological effects of SWT on the skin and liver in healthy adults.Entities:
Year: 2016 PMID: 27375769 PMCID: PMC4929740 DOI: 10.1186/s13020-016-0102-0
Source DB: PubMed Journal: Chin Med ISSN: 1749-8546 Impact factor: 5.455
Fig. 1Flow chart of present study
The anthropometric parameters in placebo and SWT treated healthy subjects
| Group | Weight (kg) | Body fat (%) | BMI (kg/m2) |
|---|---|---|---|
| Baseline | |||
| Placebo | 57.46 ± 9.43a | 29.23 ± 5.82a | 22.29 ± 3.18a |
| SWT | 57.45 ± 9.58a | 29.27 ± 5.77a | 22.35 ± 3.19a |
| 3rd month | |||
| Placebo | 57.74 ± 9.80a | 29.47 ± 5.91a | 22.39 ± 3.28a |
| SWT | 57.70 ± 9.48a | 29.15 ± 5.70a | 22.44 ± 3.21a |
| 6th month | |||
| Placebo | 57.70 ± 9.28a | 29.32 ± 6.09a | 22.32 ± 3.46a |
| SWT | 57.41 ± 9.67a | 29.25 ± 5.77a | 22.07 ± 3.43a |
Values were expressed as mean ± SD (n = 55). Data within the same column of each group sharing different superscript letters were significantly different (p < 0.05)
BMI body mass index
Various plasma oxidative indexes in placebo and SWT treated healthy subjects
| Group | TEAC (µM/mL) |
| TBARS (μM/L) |
| GSH (μM/L) |
|
|---|---|---|---|---|---|---|
| Baseline | ||||||
| Placebo | 0.34 ± 0.07a | 0.82 | 1.43 ± 0.47a | 0.87 | 14.18 ± 2.30b | 0.67 |
| SWT | 0.35 ± 0.07b | 1.40 ± 0.44a | 14.19 ± 2.48b | |||
| 3rd month | ||||||
| Placebo | 0.34 ± 0.04a | 0.001 | 1.42 ± 0.43a | 0.001 | 14.19 ± 2.79a | 0.83 |
| SWT | 0.40 ± 0.07b | 0.83 ± 0.28b | 14.31 ± 2.72a | |||
| 6th month | ||||||
| Placebo | 0.35 ± 0.03a | 0.001 | 1.45 ± 0.32a | 0.001 | 14.16 ± 2.85a | 0.88 |
| SWT | 0.59 ± 0.06a | 0.68 ± 0.23c | 14.35 ± 2.94b | |||
Values were expressed as mean ± SD (n = 55). Data within the same column of each group bearing different superscript letters were significantly different (p < 0.05)
* Student’s t test was used to assess statistical significance between placebo and Si Wu Tang (SWT)
Erythrocyte antioxidative enzymes in placebo and SWT treated healthy subjects
| Group | SOD (IU/g Hb) |
| CAT (IU/g Hb) |
| GPx (IU/g Hb) |
| GR (IU/g Hb) |
|
|---|---|---|---|---|---|---|---|---|
| Baseline | ||||||||
| Placebo | 1475.85 ± 155.91a | 0.59 | 562.82 ± 91.86a | 0.97 | 51.04 ± 8.61a | 0.99 | 10.45 ± 1.69a | 0.86 |
| SWT | 1478.86 ± 230.38c | 565.13 ± 89.02c | 51.02 ± 8.90b | 10.54 ± 1.80b | ||||
| 3rd month | ||||||||
| Placebo | 1471.12 ± 183.53a | 0.01 | 553.14 ± 66.28a | 0.001 | 51.08 ± 6.99a | 0.63 | 10.90 ± 1.98a | 0.01 |
| SWT | 1572.01 ± 238.24b | 677.61 ± 98.83b | 51.82 ± 8.97a | 11.94 ± 2.34a | ||||
| 6th month | ||||||||
| Placebo | 1475.67 ± 165.34a | 0.001 | 569.36 ± 72.39a | 0.001 | 51.61 ± 7.05a | 0.46 | 10.86 ± 2.01a | 0.02 |
| SWT | 1812.47 ± 343.74a | 803.32 ± 93.10a | 52.59 ± 6.86ab | 11.93 ± 2.66a | ||||
Values were expressed as mean ± SD (n = 55). Data within the same column of each group bearing different superscript letters were significantly different (p < 0.05)
* Student’s t test was used to assess statistical significance between placebo and Si Wu Tang (SWT)
The lipid profile in plasma of placebo and SWT treated healthy subjects
| Group | TG (mg/dL) |
| TC (mg/dL) |
| HDL-c (mg/dL) |
| LDL-c (mg/dL) |
|
|---|---|---|---|---|---|---|---|---|
| Baseline | ||||||||
| Placebo | 100.22 ± 25.60a | 0.81 | 192.85 ± 38.05a | 0.95 | 57.02 ± 11.21a | 0.87 | 114.98 ± 32.99a | 0.69 |
| SWT | 102.12 ± 28.60a | 192.05 ± 35.34a | 57.52 ± 10.25b | 113.05 ± 31.23a | ||||
| 3rd month | ||||||||
| Placebo | 97.56 ± 14.96a | 0.01 | 191.71 ± 34.63a | 0.62 | 58.60 ± 12.88a | 0.45 | 113.60 ± 34.04a | 0.83 |
| SWT | 87.27 ± 14.64b | 192.20 ± 35.55a | 59.20 ± 13.41a | 113.13 ± 32.32a | ||||
| 6th month | ||||||||
| Placebo | 97.64 ± 23.39a | 0.01 | 192.36 ± 32.85a | 0.88 | 57.51 ± 12.75a | 0.23 | 113.84 ± 32.21a | 0.48 |
| SWT | 85.89 ± 17.86b | 192.73 ± 36.25a | 59.13 ± 12.31a | 112.84 ± 33.68a | ||||
Values were expressed as mean ± SD (n = 55). Data within the same column of each group bearing different superscript letters were significantly different (p < 0.05)
* Student’s t test was used to assess statistical significance between placebo and Si Wu Tang (SWT)
The hepatic marker enzymes in plasma of placebo and SWT treated healthy subjects
| Group | GPT (U/L) |
| GOT (U/L) |
|
|---|---|---|---|---|
| Baseline | ||||
| Placebo | 19.05 ± 0.27a | 0.92 | 20.61 ± 6.37a | 0.91 |
| SWT | 19.00 ± 0.93a | 20.67 ± 6.46a | ||
| 3rd month | ||||
| Placebo | 19.27 ± 0.46a | 0.68 | 20.11 ± 6.63a | 0.72 |
| SWT | 19.44 ± 0.94b | 20.35 ± 7.74a | ||
| 6th month | ||||
| Placebo | 19.47 ± 0.79a | 0.76 | 21.42 ± 7.17a | 0.65 |
| SWT | 19.56 ± 15.11b | 21.16 ± 7.83a | ||
Values were expressed as mean ± SD (n = 55). Data within the same column of each group bearing different superscript letters were significantly different (p < 0.05)
* Student’s t test was used to assess statistical significance between placebo and Si Wu Tang (SWT)
Fig. 2The Abdominal ultrasonic image of SWT treated healthy participants. a–c represented participant no. 3, 9 and 28 at baseline with mild fatty liver, gall bladder stone and splenomegaly respectively (indicated with arrow mark). d–f represents participant no. 3, 9 and 28 at 6th month of SWT treatment with normal inference (no signs of fatty liver, gall bladder stone and splenomegaly)
Skin examination in placebo and SWT treated all healthy subjects
| Parameters | Duration | Placebo | SWT | ||
|---|---|---|---|---|---|
| Face | Arm/T-zone | Face | Arm/T-zone | ||
| Skin elasticity | Baseline | 0.806 ± 0.09a | 0.885 ± 0.08a | 0.806 ± 0.09a | 0.883 ± 0.05a |
| 6th month | 0.805 ± 0.08a | 0.874 ± 0.05a | 0.814 ± 0.08a | 0.805 ± 0.08a | |
| Skin moisture | Baseline | 45.18 ± 10.75a | 49.45 ± 9.66a | 45.18 ± 10.75a | 49.45 ± 9.66a |
| 6th month | 45.20 ± 9.86a | 49.40 ± 10.83a | 45.11 ± 8.62a | 49.08 ± 9.49a | |
| Surface water loss (g/m2/h) | Baseline | 9.43 ± 1.07a | 5.90 ± 0.66a | 9.43 ± 1.07a | 5.90 ± 2.36a |
| 6th month | 9.34 ± 1.54a | 5.52 ± 1.79a | 9.14 ± 3.73a | 4.87 ± 1.61b | |
| Sebum (μg/cm2) content | Baseline | 71.46 ± 6.42a | 163.86 ± 26.46a | 71.46 ± 6.42a | 163.86 ± 26.46a |
| 6th month | 64.02 ± 5.34a | 152.76 ± 28.37a | 62.06 ± 6.22a | 144.96 ± 22.95b | |
| Skin melanin index | Baseline | 191.47 ± 40.59a | 185.76 ± 28.02a | 191.47 ± 40.59a | 185.76 ± 31.02a |
| 6th month | 193.68 ± 34.78a | 185.22 ± 28.78a | 190.95 ± 41.44a | 184.91 ± 40.51a | |
| Skin erythema index | Baseline | 261.12 ± 49.07a | 227.68 ± 35.96a | 261.12 ± 79.07a | 227.68 ± 55.96a |
| 6th month | 266.37 ± 47.55a | 229.40 ± 34.88a | 275.55 ± 72.11b | 239.06 ± 57.14a | |
| Skin wrinkles | Baseline | 34.84 ± 2.82a | 37.41 ± 3.89a | 34.84 ± 2.82a | 37.41 ± 3.89a |
| 6th month | 34.97 ± 3.42a | 37.02 ± 3.04a | 34.06 ± 5.70a | 35.23 ± 3.20b | |
Values were expressed as mean ± SD (n = 55). Data within the same column of each group sharing different superscript letters (a, b) were significantly different (p < 0.05)
Skin examination in placebo and SWT treated healthy subjects with and without menstrual cycle
| Parameters | Duration | Placebo | Si Wu Tang (SWT) | ||||
|---|---|---|---|---|---|---|---|
| Without menstrual cycle | With menstrual cycle | ||||||
| Face | Arm/T-zone | Face | Arm/T-zone | Face | Arm/T-zone | ||
| Skin elasticity | Baseline | 0.806 ± 0.09a | 0.883 ± 0.05a | 0.774 ± 0.08a | 0.856 ± 0.06a | 0.827 ± 0.09a | 0.901 ± 0.05a |
| 6th month | 0.805 ± 0.08a | 0.874 ± 0.05a | 0.769 ± 0.08a | 0.864 ± 0.06a | 0.843 ± 0.06a | 0.895 ± 0.06a | |
| Skin moisture | Baseline | 45.18 ± 10.75a | 49.45 ± 9.66a | 44.83 ± 10.75a | 47.42 ± 9.20a | 45.41 ± 10.40a | 50.80 ± 9.86a |
| 6th month | 45.20 ± 9.86a | 49.40 ± 10.83a | 48.11 ± 8.62a | 51.08 ± 9.94a | 43.11 ± 8.62a | 47.45 ± 9.09a | |
| Surface water loss (g/m2/h) | Baseline | 9.43 ± 1.07a | 5.90 ± 0.66a | 10.02 ± 1.90a | 5.81 ± 0.98a | 9.04 ± 1.07a | 5.97 ± 1.89a |
| 6th month | 9.34 ± 1.54a | 5.52 ± 0.79a | 9.83 ± 3.26a | 4.59 ± 1.08a | 9.34 ± 3.73a | 5.06 ± 1.55b | |
| Sebum (μg/cm2) content | Baseline | 71.46 ± 6.42a | 152.86 ± 26.46a | 68.82 ± 6.53a | 162.27 ± 16.46a | 73.24 ± 6.42a | 164.91 ± 16.46a |
| 6th month | 64.02 ± 5.34a | 163.76 ± 28.37a | 58.00 ± 6.96a | 155.41 ± 30.47a | 71.42 ± 6.22a | 138.00 ± 22.95b | |
| Skin melanin index | Baseline | 191.47 ± 40.59a | 185.76 ± 28.02a | 201.02 ± 40.59a | 204.27 ± 31.02a | 185.10 ± 40.59a | 173.41 ± 27.43a |
| 6th month | 193.68 ± 34.78a | 185.22 ± 28.78a | 202.80 ± 41.44a | 203.29 ± 40.51a | 183.05 ± 41.44a | 172.65 ± 30.51a | |
| Skin erythema index | Baseline | 261.12 ± 49.07a | 227.68 ± 35.96a | 295.57 ± 49.07a | 259.23 ± 64.10a | 238.16 ± 54.70a | 206.65 ± 38.06a |
| 6th month | 266.37 ± 47.55a | 229.40 ± 34.88a | 303.66 ± 41.17b | 263.21 ± 64.58a | 256.80 ± 59.54b | 222.97 ± 45.88b | |
| Skin wrinkles | Baseline | 34.84 ± 2.82a | 37.41 ± 3.89a | 35.66 ± 3.15a | 37.69 ± 4.96a | 34.30 ± 2.48a | 37.22 ± 3.05a |
| 6th month | 34.97 ± 3.42a | 37.02 ± 3.04a | 34.83 ± 3.03a | 36.66 ± 3.92a | 34.54 ± 3.61a | 34.95 ± 2.65b | |
Values were expressed as mean ± SD (n = 55). Data within the same column of each group sharing different superscript letters (a, b) were significantly different (p < 0.05)
Fig. 3Skin surface topography viewed under ultraviolet light (Visioscan VC 98). Examination of facial and arm skin of participant 23. a, b represents the facial and arm skin of placebo group, which indicate less skin integrity, whereas c, d represents the facial and arm skin of 6 month treated SWT group, which indicate improved skin integrity and texture